The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,050.00
Bid: 12,038.00
Ask: 12,040.00
Change: -106.00 (-0.87%)
Spread: 2.00 (0.017%)
Open: 12,092.00
High: 12,178.00
Low: 12,010.00
Prev. Close: 12,156.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LIVE MARKETS-More bad news for luxury

Thu, 29th Oct 2020 10:20

Welcome to the home for real-time coverage of markets brought to
you by Reuters reporters. You can share your thoughts with us at
markets.research@thomsonreuters.com

MORE BAD NEWS FOR LUXURY (1020 GMT)

Nobody likes restrictive measures but luxury will probably
be one of the hardest hit industries after France said it would
go back to a nationwide lockdown.

“The impact of store closures in France, one of the biggest
luxury goods markets in the region, in the important Q4, and
looming risk of further closures across the continent is going
to result in negative earnings revisions for the companies in
our coverage,” a UBS research note says.

The new measures in France, which will last until Dec. 1,
will mean people have to stay in their homes except to buy
essential goods, seek medical attention, or use their daily
one-hour allocation of exercise.

(Stefano Rebaudo)

*****

EUROPE OPENS HIGHER AS TECH SHINES (0848 GMT)

European stocks manage to keep their head above water as of
now, after yesterday’s brutal selloff as focus turns to an ECB
policy meeting which might give some clues about fresh stimulus.

Tech stocks are among the best performers, despite a double
digit fall in Nokia shares, ahead of results in the
from Apple, Alphabet, Facebook and Twitter.

The Stoxx 600 index is up 0.3%, with real estate
sector leading gains up 1.1% and tech stocks up 1%. Insurers and
travel and leisure stocks are down about 0.6%.

Shares in Orange are up 5.1% after results, while
BT +7% after the company raises the lower end of its
earnings outlook for the year.

Royal Dutch Shell shares rise 3.8% after the
company said it will increase its third-quarter dividend by 4%
and reported stronger-than-expected profits.

(Stefano Rebaudo)

*****

ON THE RADAR: SHELL, AB INBEV, AIRBUS, NOKIA (0733 GMT)

European stocks are attempting to open slightly higher a day
after the biggest fall in months and hours ahead of an ECB
policy meeting.

Meanwhile senior sources in the British government expect
the vaccine, which Pfizer is co-developing with Germany's
BioNTech, could be ready to distribute before
Christmas, the Times reports. A verdict on this vaccine will be
available before the results are in on AstraZeneca Plc's
competing vaccine, it adds.

On the corporate front, a batch of good results is on its
way, with Nokia reporting third-quarter underlying
profit in line with market expectations.

Royal Dutch Shell will increase its third-quarter
dividend by 4% after stronger-than-expected profits in the
quarter.

Anheuser-Busch InBev reports a surprise increase in
beer sales in the third quarter, although profits dip and its
interim dividend payment is scrapped due to the COVID-19
pandemic.

Airbus expects to reach cash breakeven in the
fourth quarter, setting the first forward-looking target since
the start of the coronavirus crisis, after posting revenues of
11.2 billion euros versus analysts’ expectations of 11.4
billion.

Shares in Fresenius are up 2.3% in premarket trade
after the company’s third-quarter net income beats expectations.

Orange posts a 0.4% decline in its third-quarter
core operating profit, beating market expectations.

Telefonica expects a return to revenue growth in
2022 after a 785 million euro impairment charge in Argentina
dragged it to a net loss in the third quarter.

Volkswagen shares are up 1.8% in premarket trade
after the company returned to profitability in the third
quarter.

Roche shares are up 2.5% in premarket trade after
Chinese approval of Tecentriq.

Credit Suisse Group is seen down 1% after the bank
posts a 546 million Swiss francs in July-September, which is
compared with the 572 million franc median of 17 analyst
estimates compiled by the lender.

Standard Chartered booked a smaller-than-expected
40% slide in quarterly profit as the lender lowered its loan
loss expectations, also saying client demand was likely to
increase next year.

U.S. jeweller Tiffany & Co agreed with LVMH
to slightly lower the price of its acquisition by the
French luxury goods group, in a move set to end a legal dispute
between the two.

(Stefano Rebaudo)

*****

EUROPEAN STOCKS POISED FOR A REBOUND (0633 GMT)

European stock futures are in positive territory after
yesterday’s biggest fall in months on fears about the economic
impact of new restrictive measures across Europe.

Equities seem ready for a rebound ahead of an ECB policy
meeting scheduled for today which might give some clues about a
possible new round of economic stimulus.

German unemployment and inflation data, European confidence
surveys will also be closely watched, while uncertainty about
U.S. presidential elections and coronavirus worries continue to
keep investors on edge.

(Stefano Rebaudo)

*****

More News
8 Feb 2024 08:59

LONDON MARKET OPEN: Unilever up on buyback; BAT ups dividend

(Alliance News) - THE FTSE 100 in London opened slightly higher on Thursday, with earnings from British American Tobacco and Unilever boosting the index.

Read more
8 Feb 2024 08:44

TOP NEWS: AstraZeneca confident after 2023 profit more than doubles

(Alliance News) - AstraZeneca PLC on Thursday said it expects another year of strong growth after reporting pretax profit in 2023 more than doubled.

Read more
8 Feb 2024 07:58

AstraZeneca shares slip as Q4 profits miss forecasts

(Sharecast News) - Biopharma titan AstraZeneca delivered a 6% increase in sales in 2023 despite a $3.7bn decline in Covid-19 medicines revenues, as it guided to a strong pick-up in growth this year - though profits came in slightly under analysts' forecasts.

Read more
8 Feb 2024 07:50

LONDON BRIEFING: Unilever sets new buyback; Astra profit surges

(Alliance News) - Stocks in London are called to open slightly higher on Thursday, as investors eye a busy day of earnings.

Read more
2 Feb 2024 08:38

AstraZeneca celebrates latest successful trial of acoramidis in Japan

(Alliance News) - AstraZeneca PLC on Friday said positive results from a Phase 3 trial of acoramidis are consistent with global findings, bring the drug closer to regulatory submission in Japan.

Read more
2 Feb 2024 06:22

TOP NEWS: US sends drugmakers initial offers in Medicare price talks

(Alliance News) - The US government said it was making initial offers to drugmakers Thursday as part of Medicare negotiations meant to lower the prices many older Americans would pay for 10 medicines.

Read more
1 Feb 2024 15:52

UK earnings, trading statements calendar - next 7 days

Friday 2 February 
YouGov PLCTrading Statement
Monday 5 February 
Home REIT PLCTrading Statement
Porvair PLCFull Year Results
Trident Royalties PLCTrading Statement
Vodafone Group PLCTrading Statement
Tuesday 6 February 
Alumasc Group PLCHalf Year Results
BP PLCFull Year Results
Filtronic PLCHalf Year Results
Mattioli Woods PLCHalf Year Results
Renishaw PLCHalf Year Results
Virgin Money UK PLCTrading Statement
Wednesday 7 February 
Ashmore Group PLCHalf Year Results
Barratt Developments PLCHalf Year Results
HydrogenOne Capital Growth PLCTrading Statement
Phoenix Spree Deutschland LtdTrading Statement
PZ Cussons PLCHalf Year Results
Smurfit Kappa Group PLCFull Year Results
UK Commercial Property REIT LtdTrading Statement
Thursday 8 February 
Anglo American PLCTrading Statement
AstraZeneca PLCFull Year Results
British American Tobacco PLCFull Year Results
Compass Group PLCTrading Statement
Redrow PLCHalf Year Results
SSE PLCTrading Statement
Unilever PLCFull Year Results
  
Comments and questions to newsroom@alliancenews.com
  
A full 21-day events calendar is provided each day with a subscription to Alliance News UK Professional.
  
Copyright 2024 Alliance News Ltd. All Rights Reserved.

Read more
29 Jan 2024 08:19

TOP NEWS: AstraZeneca, Daiichi's Enhertu granted priority review in US

(Alliance News) - AstraZeneca PLC on Monday said its cancer drug conjugate received priority review by the Food & Drug Administration in the US for patients with metastatic HER2-positive solid tumours.

Read more
22 Jan 2024 11:45

BioNTech challenges AstraZeneca with breast cancer precision drug trial

FRANKFURT, Jan 22 (Reuters) - BioNTech and its partner Duality Biologics said on Monday they initiated a late-stage trial testing their precision drug against a certain type of breast cancer, taking on a rival partnership between AstraZeneca and Daiichi Sankyo.

Read more
19 Jan 2024 09:28

TOP NEWS: AstraZeneca's Voydeya receives approval in Japan for PNH

(Alliance News) - AstraZeneca PLC on Friday said its inhibitor Voydeya, also known as danicopan, received approval in Japan for adults with paroxysmal nocturnal haemoglobinuria, or PNH.

Read more
16 Jan 2024 17:17

FTSE 100 hits one-month low, precious miners biggest drag

FTSE 100 down 0.5%, FTSE 250 flat

*

Read more
16 Jan 2024 16:17

London close: Stocks finish lower as wage growth eases

(Sharecast News) - London's stock markets finished in the red on Tuesday, as investors assessed the latest UK jobs data.

Read more
16 Jan 2024 11:58

LONDON MARKET MIDDAY: FTSE 100 falls despite cooler UK wage growth

(Alliance News) - The FTSE 100 in London was down at midday Tuesday, as investors nervously eye Wednesday's UK inflation data and what it will mean for interest rates.

Read more
16 Jan 2024 09:14

LONDON BROKER RATINGS: UBS raises GSK and cuts AstraZeneca

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
16 Jan 2024 08:15

UBS downgrades AstraZeneca to 'sell'

(Sharecast News) - UBS has downgraded AstraZeneca and upgraded rival GSK as part of its latest review of the European pharmaceutical sector.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.